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Breast cancerIn the course of breast cancer global gene expression studies, we identiﬁed an uncharacterized gene known
as RHBDD2 (Rhomboid domain containing 2) to be markedly over-expressed in primary tumors from patients
with recurrent disease. In this study, we identiﬁed RHBDD2 mRNA and protein expression signiﬁcantly
elevated in breast carcinomas compared with normal breast samples as analyzed by SAGE (n=46) and
immunohistochemistry (n=213). Interestingly, specimens displaying RHBDD2 over-expression were
predominantly advanced stage III breast carcinomas (p=0.001). Western-blot, RT-PCR and cDNA sequencing
analyses allowed us to identify two RHBDD2 alternatively spliced mRNA isoforms expressed in breast cancer
cell lines. We further investigated the occurrence and frequency of gene ampliﬁcation and over-expression
affecting RHBDD2 in 131 breast samples. RHBDD2 gene ampliﬁcation was detected in 21% of 98 invasive
breast carcinomas analyzed. However, no RHBDD2 ampliﬁcation was detected in normal breast tissues
(n=17) or breast benign lesions (n=16) (p=0.014). Interestingly, siRNA-mediated silencing of RHBDD2
expression results in a decrease of MCF7 breast cancer cells proliferation compared with the corresponding
controls (p=0.001). In addition, analysis of publicly available gene expression data showed a strong
association between high RHBDD2 expression and decreased overall survival (p=0.0023), relapse-free
survival (p=0.0013), and metastasis-free interval (p=0.006) in patients with primary ER-negative breast
carcinomas. In conclusion, our ﬁndings suggest that RHBDD2 over-expression behaves as an indicator of poor
prognosis and may play a role facilitating breast cancer progression.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
In the course of recent breast cancer global gene expression studies
we identiﬁed a distantly related rhomboid-like gene known as RHBDD2
(Rhomboid domain containing 2) located at the 7q11.23 chromosomal
region, to be markedly over-expressed in primary invasive carcinomas
from patients that recurred within 6 years of follow-up [1].
The human genome contains several rhomboid-like genes which
can be phylogenetically grouped in three major classes [2]. The ﬁrst
class, includes the true active rhomboids genes that are subdivided into
secretase (e.g. RHBDL-1/-2/-3 and RHBDD1 genes) and PARL-type
subfamilies. The second class is composed of novel inactive rhomboids
members, recently named as iRhoms group (e.g. RHBDF-1/-2 genes).
The third group includes a small number of other distant evolutionary
related and uncharacterized genes (e.g. RHBDD-2/-3) for which there
is no evidence that they are active proteases. Rhomboid-like proteinsunológicas Básicas y Aplicadas
ional de La Plata, Calle 60 y 120,
).
ll rights reserved.function in diverse processes including quorum sensing in bacteria,
mitochondrial membrane fusion/apoptosis (PARL) and stem cell diffe-
rentiation in eukaryotes [3,4]. Also, rhomboid-like proteins have been
recently linked to human diseases, including early-onset blindness,
diabetes, and parasitic diseases [5]. However, the biological functions of
the mammalian rhomboid-like family remains to be determined.
Here we present data supporting the role of RHBDD2 as a novel
breast cancer-related gene. We demonstrate that RHBDD2 is over-
expressed at the mRNA and protein levels in breast cancer samples and
in some of these cases due to gene ampliﬁcation. Interestingly, analysis
of publicly available breast cancer gene expression databases indicates
that RHBDD2 is over-expressed in estrogen receptor-negative breast
carcinomas from patients with poor prognosis. Finally, we show that in
vitro RHBDD2 silencing regulates cell proliferation of breast cancer cells.
2. Material and methods
2.1. Serial analysis of gene expression database mining
To perform a comparative analysis of the human Rhomboid-like
family members expressed in breast tissue, we analyzed 46 breast
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epithelium, 8 ductal carcinoma in situ (DCIS), and 33 invasive ductal
carcinomas (IDC). To this end, we combined 29 breast cancer SAGE
libraries generated by us at a resolution of 100,000 tags per library
(Aldaz Laboratory) with 17 SAGE libraries (generated at the Polyak
Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA) down-
loaded from the Cancer Genome Anatomy Project — SAGE Genie
database (http://cgap.nci.nih.gov/SAGE/). SAGE data management
and tag-to-gene matching for RHBDD1 (AGGGCAGGGA), RHBDD2
(TTGTCTGCCT), RHBDD3 (CTGCCCTAGT), RHBDL1 (TGGTGGCCGC),
RHBDL2 (AGTTCAAGAC), RHBDL3 (TTGCTCCCCG), RHBDF1 (TGGCCAA-
TAA), RHBDF2 (GATTAAATAA), and PARL (GCTATGCTCC) were per-
formed with a suite of web-based SAGE library annotation tools
developed by us (http://spi.mdacc.tmc.edu/bitools/about/sage_lib_
tool.html). To enable the visualization and illustration of our analyses,
we used the TIGR MultiExperiment Viewer (MeV 3.0) software (The
Institute for Genomic Research, Rockville, MD, USA). This tool was
employed for normalization and average clustering of the SAGE data.
2.2. RHBDD2 antibody production, Western-blot and
immunoﬂuorescence analyses
A polyclonal antibody against RHBDD2 was generated by sequen-
tial immunizations of two rabbits with three puriﬁed KLH-conjugated
peptides (GenScript Corp., NJ, USA). Peptides were synthesized based
on RHBDD2 protein sequence (NP065735) corresponding to residues
30–43 (EDRQPASRRGAGTT), residues 253–266 (ASGAEARSDLPLQP),
and residues 393–406 (HQGLQAPRSPPGSP). The polyclonal antibody
was puriﬁed from the immune serum by afﬁnity chromatography. The
primary antibody speciﬁcity was further demonstrated by Western-
blot, immunoﬂuorescence and siRNA analyses using breast cell lines
(see below Figs. 2 and 6B).
Total protein extracts were prepared from a set of 7 breast normal
and cancer cell lines (HME87, MCF10, MCF7, ZR75-30, T47D, BT47A,
and BT549). As normal controls we also included human breast
epithelial organoid protein extracts, obtained from three independent
cosmetic mammoplastic specimens (B26, B27, and B28). Total cell
protein lysates were made from frozen tissues using RIPA buffer
(50 mM Tris pH 7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 1%
Triton X-100, and 0.1% SDS) containing protease inhibitor cocktail
(Roche, Mannheim, Germany). For Western blot, 50 µg of total protein
was separated by 12.5% SDS-PAGE and transferred to PVDF mem-
branes (Millipore, Billerica, MA). Immunodetection was performed
using Protein Detector™ (KPL, Gaithersburg, MD) Western blotting
reagents as described by the manufacturer. RHBDD2 protein was de-
tected using an anti-RHBDD2 polyclonal primary antibodies and HRP
conjugated anti-rabbit secondary antibody (KPL, 1:2000) followed by
chemiluminescence autoradiography. Beta-actin protein (ACTB) was
detected using monoclonal anti-actin antibody (ICN Biomedicals,
Burlingame, CA, 1:1000) and HRP conjugated anti-mouse secondary
antibody (KPL, 1:5000).
For immunoﬂuorescence analysis, MCF7 and MCF10 smears from
exponentially growing cells were prepared on glass slides and then
ﬁxed in cold acetone for 10 min. Anti-RHBDD2 polyclonal antibody
was added to the slides at a 1:250 dilution, and incubated at room
temperature during 1 h. Detection was performed using FITC-labeled
secondary anti-rabbit IgG antibodies following standard immuno-
ﬂuorescence methods.
2.3. RT-PCR and cDNA sequencing analyses
Total RNA was isolated from eleven frozen normal breast tissue
derived from cosmetic mammoplastic specimens and three breast
cancer cell lines (MCF7, T47D and ZR75) using TRI Reagent® (MCR Inc.,
USA). Quality control of RNA integrity was made by running out
RNA samples onto formaldehyde denaturing 1.2% agarose gel andethidium bromide staining. Following DNAse I digestion, template
cDNAs were synthesized using SuperScript™ First-strand Synthesis
System (Invitrogen, USA). For mRNA expression analysis, we designed
three combinations of PCR primers (Forward-1/Reverse, Forward-2/
Reverse, and Forward-3/Reverse) that spanned all exons of the
RHBDD2 transcript. The primer sequences are as follows: Forward-1
5′-CATCCGCCACCTTCTTCACT-3′; Forward-2 5′-GATCTTCGC-
CATCTTCTCCG-3′; Forward-3 5′-GCCTGATGAGGAGGATATCCG-3′;
and Reverse 5′-AATACACCGTGCCAGGGCT-3′.
The isolated RT-PCR products were sequenced in both directions
using the DYEnamic ET Dye Terminator Cycle Sequencing Kit and
analyzed on a MEGABACE 1000 DNA sequencer (GE Healthcare
Biosciences), according to the manufacturer's instructions. The
obtained DNA sequences were further aligned and compared with
the RHBDD2 genomic sequence (accession no. NT007933.14) to
determine the exon–intron structure of RHBDD2. Experiments were
performed in triplicate for each data point and beta-actin (ACTB)
mRNA was used as reference.
2.4. Inmunohistochemistry analyses of RHBDD2 protein expression
in tissues
Formalin-ﬁxed parafﬁn-embedded breast tissue samples were
obtained from the MD Anderson Cancer Center — USA (61 samples),
and from different hospitals associated to the National University of La
Plata — Argentina (152 samples). The use of human tissue blocks and
clinical records was approved by the appropriate institutional
committees. By pooling both sample sets we were able to analyze a
total of 213 cases including: 44 normal breast tissues (18 normal
tissues from individuals without breast cancer, and 26 normal tissues
adjacent to invasive breast cancers),18 benign breast disease (7 benign
mammary dysplasia, and 11 breast ﬁbroadenomas), 26 ductal
carcinomas in situ (DCIS), 109 primary invasive ductal carcinomas
(IDC) and 16 lymph node metastasis specimens (LNM). Stage at time
of diagnosis was based on the TNM classiﬁcation.
Prior to immunostaining, endogenous peroxidase activity was
blocked with 3% H2O2 in water for 10 min; heat-induced epitope
retrievewas performedwith 10mMCitrate buffer pH 6.0 for 10min in
a microwave oven followed by a 20 min cool down. In order to block
non-speciﬁc antibody binding, the slideswere incubatedwith 10% goat
serum in PBS for 30 min. Primary polyclonal RHBDD2 antibody was
used at 1:250 dilution. Inmunodetection was performed with the
DakoCytomation LSAB+System-HRP (Dako, Denmark). Sectionswere
counterstained with hematoxylin (Sigma, USA) and examined by light
microscopy. Staining intensity was graded as negative (−), weak (+),
moderate (++), or strong (+++). The number of optical ﬁelds in a
specimen that were positively stained was expressed as a percentage
of the total number of optical ﬁelds containing tissue. A reaction was
considered positive when more than 5% of the breast epithelial cells
were stained. The staining of cytoplasm, plasma membrane and
nucleus was evaluated; cells were considered positive when at least
one of these components was stained. IHC analysis of ESR1 (ER-alpha)
was performed byusing a primarymonoclonal ERα antibody (ER-6F11,
Novocastra — UK) at 1:50 dilution as was previously described [6].
2.5. RHBDD2 gene ampliﬁcation analysis
DNA was isolated from 131 formalin-ﬁxed parafﬁn-embedded
samples (17 normal samples, 16 benign lesions and 98 invasive
breast carcinomas) previously analyzed for RHBDD2 protein expres-
sion by IHC. RHBDD2 gene ampliﬁcation was estimated using a
competitive PCR method [7,8]. In the duplex PCR reactions, RHBDD2
gene located at 7q11.23, and Solute carrier family 13A1 gene
(SLC13A1, gene not known to be associated with cancer) located at
7q31–q32, is used as the intra-chromosomal arm reference gene.
SLC13A1 was chosen as reference gene because its chromosome
Fig. 2. RHBDD2 protein expression in normal and breast cancer cell lines. (A) Protein
extracts were separated by 12.5% SDS-PAGE and transferred to PVDF membranes.
RHBDD2 protein was detected using a polyclonal anti-RHBDD2 antibody developed by
our laboratory. The membrane was then probed with mouse monoclonal anti-actin
antibody for normalization of differences in protein loading. Three normal human
protein extracts prepared from breast organoids were included (B25, B26, and B27). The
full-length RHBDD2 protein (isoform 1) and the predicted splicing variant (isoform 2)
are indicated. (B) Immunoﬂuorescence and immunocytochemistry detection of
RHBDD2 displayed a vesicular pattern compatible with an ER-like distribution in
MCF7 cells (see Supplementary Fig. 1). MCF10 cell smears were used as the negative
control demonstrating non cross-reactivity of the primary antibody. MCF7 cells without
RHBDD2 polyclonal antibody was also used as negative control of the reaction (MCF7-
NegCt). The nuclei were counterstained with propidium iodide (red ﬂuorescence).
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on array-CGH Progenetix database [9]. Duplex PCR ampliﬁcation was
done in a ﬁnal volume of 50 µl using 10 ng of cDNA, 1.25 U of Taq DNA
polymerase (Promega, Madison, Wisconsin — USA), 2.5 mM MgCl2,
200mMof each dNTP and 12.5 pmol of both primer pairs in PCR buffer
(20mM, Tris–HCL pH 8.4, and 50mMKCL). The primers for both genes
are RHBDD2-Forward 5′-CATCCGCCACCTTCTTCACT-3′, RHBDD2-
Reverse 5′-TGGTGATGAGGACCGAGACA-3′ (amplicon of 259 bp),
SLC13A1-Forward 5′-TCGCCGATTTCTCTTCGTG-3′ and SLC13A1-
Reverse 5′-GCCAGGCAGTTAAACAGCAAA-3′ (amplicon of 157 bp).
The reactions were cycled as follows: 1 cycle of 94 °C for 2 min;
25 cycles of 40″ at 92 °C, 40″ at 57 °C, and 40″ at 72 °C. Detection of the
ampliﬁed fragments was made by electrophoresis onto a 2% agarose
gel and SYBR-Safe™ DNA staining (Invitrogen — USA). The Kodak
Digital Science 1D Image Analysis Softwarewas used to determine the
ratio between net intensity bands of RHBDD2 and SLC13A1 amplicons.
Samples were considered to be affected by genomic ampliﬁcation for
RHBDD2when the ratio between net intensity bands was greater than
+3 SD (99% conﬁdence interval, pb0.001) relative to the average
value determined from 11 normal breast control samples. Experi-
ments were performed in triplicate for each data point.
2.6. In silico RHBDD2 gene expression and clinical data analysis
To further investigate correlations of transcriptional up-modula-
tion of RHBDD2 gene and clinicopathologic parameters on larger
breast carcinoma sets, data were obtained from a publicly available
breast cancer microarray study [10]. Clinicopathologic and gene
expression data from 295 primary invasive breast carcinomas (226
ER-positive and 69 ER-negative carcinomas) were collected from the
Rosetta Inpharmatics website (http://www.rii.com/publications/
2002/nejm.html). Two groups of patients were derived by using the
median expression value of the Log2 ratio overall distribution for
RHBDD2 probe (NM_020684) (RHBDD2median=0.017; high expres-
sion, greater than 0.017; and low expression, less than 0.017). Kaplan–
Meier analysis was assessed with both groups using the Van de Vijver
et al. data by means of SPSS® statistic software (SPSS Inc., Chicago).
2.7. RHBDD2 gene silencing and cell proliferation assay
Three siRNAs of 19-mer against RHBDD2 mRNA corresponding to
coding sequences starting at positions 1326 (siRNA-R1: 5′-CUGUGUU-
GGGUACUUUGAUdTdT-3′), 340 (siRNA-R2: 5′-GUCUACGAGAAUCCC-
AUCUdTdT-3′) and 1050 (siRNA-R3: 5′-GCAGAACCACUUUGGUCCA-
dtdt-3′) relative to the cDNA sequence AF226732 were synthesized
(Bioneer Inc, Korea). The AccuTarget™ biotin-labeled negative controlFig. 1. Digital Northern analysis of human rhomboid-like family members based on SAGE da
invasive ductal carcinomas) (A). The color scale at the bottom of the picture is used to repr
ANOVA test of RHBDD2 expression among normal breast tissue, ductal carcinoma in situ (DC
were detected in IDC compared with normal breast tissue group (pb0.008).siRNA (siRNA-NegCt: 5′-CCUACGCCACCAAUUUCGUdTdT-3′) (Bioneer
Inc, Korea) that exhibits no homology to any human genome sequence
was used as a non-silencing reference. In addition, we included a
positive control siRNA sequence (Termo Scientiﬁc Dharmacon, USA),ta in 46 breast samples (4 normal breast epithelium, 8 ductal carcinoma in situ and 34
esent relative expression level based on numbers of transcripts (tags) per libraries. (B)
IS) and primary invasive breast carcinomas (IDC). High expression levels of RHBDD2 tag
Fig. 3. Identiﬁcation of two RHBDD2 mRNA isoforms. (A) Schematic representation of human RHBDD2 genomic structure and the corresponding mRNA isoform structure predicted
in silico based on RHBDD2 EST database searching. (B) RT-PCR analysis inMCF7, T47D, and ZR75 breast cancer cell lines. Three pairs of PCR primers (F1 / R, F2 / R and F3 / R), based on
EST sequences were used to amplify the RHBDD2 transcript from cDNA. Alternative splicing involving exons 1 and 2 generates the isoform 2. (C) RHBDD2 RT-PCR of ﬁve normal breast
tissue (N1–N5) and three breast cancer cell lines (MCF7, T47D, ZR75). (D) Alignment of the MCF7 cDNA sequences among RHBDD2 isoforms.
991M.C. Abba et al. / Biochimica et Biophysica Acta 1792 (2009) 988–997
Table 1
RHBDD2 protein expression in breast samples as related to histopathological
characteristics.
Histopathology Protein expression n (%) Cases
Absent Weak Moderate Strong
Normal epithelium 13 (72%) 4 (22%) 0 (0%) 1 (6%) 18
Normal adjacent IDC 4 (15%) 4 (15%) 12 (46%) 6 (23%) 26
Benign lesions 6 (33%) 6 (33%) 4 (22%) 2 (11%) 18
DCIS 1 (4%) 7 (27%) 11 (42%) 7 (27%) 26
IDC 31 (28%) 34 (31%) 23 (21%) 21 (20%) 109
LNM 0 (0%) 4 (25%) 4 (25%) 8 (50%) 16
Total 55 59 54 45 213
992 M.C. Abba et al. / Biochimica et Biophysica Acta 1792 (2009) 988–997which signiﬁcantly reduces the lamin A/C protein level by N70%
without affecting the MCF7 cell phenotype or viability. MCF7 cells
were seeded on 12 well plate format in Opti-MEM I Reduced Serum
Medium (Invitrogen, USA), when cells reached 40% conﬂuence, they
were transfected with 40 pmoles/µl of siRNA mixed with TransIT-
TKO® Transfection Reagent according to the manufacturer's protocol
(Mirus, USA). Transfection efﬁciency was monitored using biotiny-
lated siRNA and FITC-avidin for detection. RHBDD2 mRNA and pro-
tein levels and effects on cells were analyzed by RT-PCR and
immunoﬂuorescence at 48 h post-transfection respectively. Cell
proliferation was assessed using the CellTiter 96® Aqueous Non-
Radioactive Cell Proliferation Assay (Promega, USA), that is a colori-
metric method for determining the number of viable cells in pro-
liferation. In addition, cell viability was monitored daily by the trypan
blue exclusion test.
2.8. Additional bioinformatics and statistical analyses
We employed the ASAP online database resource (Alternative
Splicing Annotation Project) for the in silico analysis of RHBDD2 exon–
intron structure (http://www.bioinformatics.ucla.edu/ASAP). ASAP
is based on human genome-wide analyses of alternative splicing
events based on detailed alignment of EST/cDNA sequences onto the
genomic sequence [11].
To enable visualization and illustration of the 7q11.2 chromosome
region in some breast cancer cell lines from Pollack's array-CGH data
[12], we used the VAMP software (Visualization and Analysis of array-
CGH, transcriptome and otherMolecular Proﬁles) (http://bioinfo-out.
curie.fr/actudb). VAMP is a graphical user interface for visualization
and analysis of genomic proﬁles [13]. The chromosome 7 array-CGH
proﬁles previously generated by Pollack et al. [12] from MCF7, T47D
and ZR75 breast cancer cell lines were download from the ACTuDB
database at the same website [14]. The frequency of DNA gains/losses
affecting the chromosome region 7q11.23 was determined from a
cumulative set of 552 IDC analyzed by array-CGH based on a publicly
available Progenetix database (http://www.progenetix.net) [9].
Univariate analysis of clinical–pathological parameters based on
RHBDD2 gene ampliﬁcation/expression was determined by Fisher's
exact test. Ordinal-by-ordinal associations have been assessed by
Kendall's tau-b test. The basic signiﬁcance level was ﬁxed at pb0.05
and all data were analyzed using SPSS® statistic software (SPSS Inc.,
Chicago).
3. Results
3.1. Human rhomboid family members expressed in breast epithelial cells
We analyzed the rhomboid-like family member gene expression
proﬁle in a set of normal and breast cancer SAGE libraries. Among the
rhomboid family members, RHBDD2 and RHBDF1 were the most
frequently expressed rhomboid-like genes in breast SAGE libraries
(Fig. 1a). Speciﬁcally, RHBDD2 was detected as being expressed in
100% of breast cancer cases (34 out of 34) according to SAGE database
analyses. interestingly, among the rhomboid genes only RHBDD2 was
identiﬁed as over-expressed in primary invasive breast carcinomas
compared with normal breast samples (pb0.008) (Fig. 1b). No
association was detected between the expression of this transcript
and ERα status (pN0.05).
3.2. RHBDD2 expression analysis in normal and breast cancer cell lines
and identiﬁcation of alternatively spliced mRNA isoforms
We performed Western-blot analysis in normal and breast cancer
cell lines using a custom-design polyclonal antibody against the
RHBDD2 protein.We identiﬁed the expected 47 kDa product as well as
a smaller protein product at approximately 40 KDa. MCF7 and T47Dcell lines showed high levels of RHBDD2 protein expression, while
normal breast organoids (B26, B27, and B28) and non-transformed
breast cell lines (MCF10A and HME87) showed weak and undetect-
able levels of RHBDD2 protein expression respectively (Fig. 2A).
RHBDD2 immunostaining displayed a granulate/vesicular pattern
compatible with an endoplasmic reticulum-like distribution with
accumulation in the perinuclear space of MCF7 and T47D cells (Fig. 2B
and Supplementary Fig. 1). MCF10 cell smears were used as the
negative control of the reaction demonstrating non cross-reactivity of
the primary antibody (Fig. 2B).
We decided to investigate whether the different protein products
were results of alternatively spliced RHBDD2 transcripts (isoform).
RHBDD2 alternative splicing prediction based on ASAP (Alternative
Splicing Annotation Project) bioinformatics analysis revealed two
putative isoforms, here named as isoform 1 (full-length RHBDD2
mRNA) and isoform 2 (alternatively spliced isoform) (Fig. 3A). To
validate these ﬁndings, we ﬁrst performed an RT-PCR analysis in
MCF7, T47D and ZR75 breast cancer cell lines. Three pairs of PCR
primers, based on EST sequences were used to amplify the RHBDD2
transcript from cDNA, and the products were sequenced. MCF7 and
T47D cell lines showed high expression levels of RHBDD2 with any
combination of PCR primers used for RT-PCR analysis (Fig. 3B, C).
Interestingly, primer pairs F1/R located on the ﬁrst and last exons of
RHBDD2 mRNA respectively, result in two PCR products of approxi-
mately 1100 and 900 bp in MCF7 and T47D cell lines (Fig. 3A). The
luminal-tumor derived cell line ZR75 showed weak RHBDD2 mRNA
expression. However, primer pairs F2/R and F3/R result in a unique
RT-PCR product of 720 bp and 369 bp respectively as it was expected
(Fig. 3B, C) and conﬁrmed by direct DNA sequencing (data not
shown). Bi-directional sequence analysis was performed on each
puriﬁed RT-PCR product from the MCF7 cell line. Comparison of these
sequences with the publicly available RHBDD2 genomic sequence
(accession no. NT007933.14) conﬁrmed gene identity for each PCR
fragment and revealed that these two transcripts detected with the
primer pairs F1/R were generated by alternative RNA splicing of exons
1 and 2 of RHBDD2 (Fig. 3D). These data suggest that the low protein
product observed in the Western-blot analysis represents true
RHBDD2 protein, demonstrating that the antibody used in our study
detected the full-length RHBDD2 protein (isoform 1) as well as the
alternative splicing variant (isoform 2) (Fig. 2). In addition, this RT-
PCR analysis showed undetectable or low expression of RHBDD2 gene
in normal breast tissues analyzed (Fig. 3C). These data corroborate the
SAGE analysis showing that RHBDD2 mRNA/protein expression is
highly elevated in some breast cancer cells compared with normal
breast samples.
3.3. Increased RHBDD2 protein expression in breast cancer clinical
specimens
To further investigate the relevance of RHBDD2 protein expres-
sion in breast cancer, we analyzed 213 breast tissue sections by
immunohistochemistry (Table 1 and Fig. 4). We identiﬁed a statis-
tical signiﬁcant increase in RHBDD2 protein expression from normal
Fig. 4. RHBDD2 immunohistochemical staining in (A) normal breast adjacent tumor (×100), (B) hyperplastic breast lesion (×100), (C) ductal carcinoma in situ (×400), (D, E) ERα-
negative invasive ductal carcinomas with RHBDD2 gene ampliﬁcation (×100 and ×400 respectively), and (F) lymph node metastasis sample (×400). As negative control for
immunohistochemical staining we used a tissue sample, without primary antibody incubation (G), derived from serial sections of a RHBDD2-positive invasive breast carcinoma (H).
993M.C. Abba et al. / Biochimica et Biophysica Acta 1792 (2009) 988–997breast tissues to breast cancer metastasis specimens analyzed
(p-trend=0.01).
RHBDD2 protein expression was detected in 61% (27 out of 44) of
normal breast samples analyzed. Interestingly, 95% (17 out of 18) of
normal breast epithelium obtained from cosmetic mammoplasties,
showed negative or weak RHBDD2 protein expression (Table 1). In
contrast, 69% (18 out of 26) of normal breast tissue adjacent to
invasive ductal carcinomas showed moderate or strong RHBDD2
expression, and only 31% (8 out of 26) of these samples showednegative or weak RHBDD2 immunostaining (Table 1). Statistical ana-
lysis of RHBDD2 protein expression between normal breast epi-
thelium and normal breast adjacent IDC showed highly signiﬁcant
differences (p=0.0001). RHBDD2 immunostaining showed a granu-
late reaction that was mostly localized in the perinuclear space and in
the membrane.
Benign mammary dysplasia and ﬁbroadenoma lesions displayed
negative or weak RHBDD2 protein expression in approximately 66%
(12 out of 18) of the analyzed cases, while moderate or strong
994 M.C. Abba et al. / Biochimica et Biophysica Acta 1792 (2009) 988–997RHBDD2 protein expression was predominantly detected in 69%
(18 out of 26) of the ductal carcinomas in situ analyzed (pb0.01)
(Table 1).
Among IDC samples, negative RHBDD2 expression was detected in
28% of the cases (31 out of 109). However, when RHBDD2 expression
and tumor stage were considered, we observed a statistically
signiﬁcant correlation between high levels of RHBDD2 and more
clinically advanced cancer (p=0.001). In this sense, 92% of IDC
negative for RHBDD2 expression were early-stage (I and II) breast
carcinomaswhile only 9% of tumor stage III were negative for RHBDD2
protein expression. Furthermore, 50% of IDC with tumor stage III
showedmoderate or strong RHBDD2 protein expression. Interestingly,
RHBDD2 protein expression was detected in all breast lymph node
metastasis samples (16 out of 16) displaying a moderate or strong
RHBDD2 expression in approximately 75% (12 out of 16) of the
analyzed samples (Table 1 and Fig. 4). Non-statistical signiﬁcant
association was detected between RHBDD2 protein expression and
ERα status as well as histologic tumor grade (pN0.05).
Overall, these data are in agreement with the SAGE proﬁling
analysis, indicating that a high proportion of invasive breast carcino-
mas expressed signiﬁcantly increased levels of RHBDD2 protein
compared with normal breast samples. More importantly, strong
RHBDD2 protein expression was highly associated with primary in-
vasive breast carcinomas with axillary lymph node metastases.
3.4. RHBDD2 gene is ampliﬁed in correlation with over-expression in
breast cancer cells
Microarray-based comparative genomic hybridization evidence is
available reporting the ampliﬁcation of the chromosomal regionFig. 5. RHBDD2 gene ampliﬁcation analysis in breast samples. (A) Visualization of 7q11.2 micr
Pollack et al. study [12]. Red lines indicate chromosomal regions of gain. These data suggest a
showed RHBDD2 gene ampliﬁcation in MCF7 and T47D breast cancer cell lines in agreem
conﬁrming the RHBDD2 and SLC13A1 gene sequence identities. (D) RG-PCR analysis in norma
invasive breast carcinomas (samples 996, 1516 and 1495) showed RHBDD2 gene ampliﬁcati7q11.23 in breast cancer cell lines and primary breast carcinomas
[12,15]. To investigate the frequency of DNA gains/losses affecting the
chromosome region 7q11.23, we performed a pooled re-analysis of
552 invasive breast carcinomas previously analyzed by array-CGH,
available at Progenetix online database. Pooled estimates showed gain
of chromosome region 7q11.23 in 11% of the analyzed cases (61 out of
552 IDC). The Visualization and Analysis of array-CGH, transcriptome
and other Molecular Proﬁles (VAMP) [13] resource was employed for
microarray-CGH data analysis of chromosome region 7q11.23 from
MCF7, T47D and ZR75 breast cancer cell lines. In silico analysis of
Pollack's data [14] identiﬁed a gain of chromosome regions 7q11.22–
7q11.23 including the RHBDD2 gene region in MCF7 and T47D cell
lines (Fig. 5A). These data are in agreement with our Western-blot
observations.
We used a competitive PCR method based on duplex PCR of
RHBDD2 (target) and SLC13A1 (control) genes for the quick inter-
rogation of human breast tumor DNA for the presence or absence of
genomic ampliﬁcation of speciﬁc genes affecting the region of
interest. We analyzed DNA obtained from breast cancer cell lines
and 131 samples (17 normal tissues, 16 benign lesions, 98 IDC)
previously analyzed for protein expression by IHC. The DNAs from all
samples were adequately ampliﬁed by the SLC13A1 control primers.
Competitive PCR analysis showed RHBDD2 gene ampliﬁcation in
MCF7 and T47D breast cancer cell lines, while no ampliﬁcation was
detected for the ZR75 cancer line, in agreement with the array-CGH
data and validating the method (Fig. 5B). It is important to note,
that RHBDD2 mRNA and protein expression are highly elevated in
both breast cancer cell lines (MCF7 and T47D), thus conﬁrming a
direct association between RHBDD2 gene ampliﬁcation and over-
expression. RHBDD2 genomic ampliﬁcation was detected in 21%oarray-based CGH proﬁle of MCF7, T47D and ZR75 breast cancer cell lines obtained from
region of genomic gain located at 7q11.23 involving the RHBDD2 gene. (B) RG-PCR assay
ent with Pollack data. (C) DNA sequence chromatogram of isolated PCR amplicons
l breast tissues (N1–N5), and seven primary invasive breast carcinomas. Note that three
on (black arrows).
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However, no ampliﬁcation in RHBDD2 was identiﬁed in any of 17
normal and 16 benign tissue samples analyzed. Statistical analysis
identiﬁed a signiﬁcant positive association between RHBDD2 gene
ampliﬁcation and RHBDD2 protein expression assessed by IHC
studies (pb0.05).3.5. RHBDD2 gene silencing in vitro leads to reduced cell proliferation
rate
To investigate whether RHBDD2 gene expression plays any role
associated to cell proliferation; a knock-down assay was performed
with speciﬁc siRNA sequences targeting RHBDD2 mRNA in MCF7
breast cancer cell line. Cells were treated with optimal concentrations
of RHBDD2 siRNA and examined the number of viable cells 48 h after
transfection.
RT-PCR and immunoﬂuorescence analyses demonstrated an
effective depletion of RHBDD2 at mRNA and protein levels in MCF7
by using the siRNA-R1 and siRNA-R3 sequences compared with the
negative control siRNA (Fig. 6A and B). MCF7 cells in the control
group were treated with the siRNA-Ct, which had a randomized
nucleotide sequence that had no signiﬁcant homology to the human
genome. siRNA-R1 and siRNA-R3 treated cells showed a signiﬁcant
decrease in proliferation 48 h after transfection compared to
negative or positive control siRNAs (Fig. 6C). In addition, siRNA-R1
and siRNA-R3 treatments did not affect cell viability or morphology
of MCF7 breast cancer cells. This result suggests that RHBDD2
function is related to regulation of cell proliferation in MCF7 breast
cancer cells.Fig. 6. RHBDD2 knock-down analysis in MCF7 breast cancer cell line. (A) RT-PCR analysis of
and three RHBDD2 siRNA sequence treatments (siRNA-R1, siRNA-R2 and siRNA-R3). (B) Imm
Ct, siRNA-R1 and siRNA-R3 treatments. The nuclei were counterstained with propidium iod
cells at 48 h after siRNA transfection, expressed as absorbances at 492 nmmeasured using th
point represents the mean±2 SE of 12 replicates.3.6. RHBDD2 expression analysis and its clinical relevance as
poor-prognosis marker
To further explore the clinical relevance of gene expression in
human breast carcinomas, we evaluated information from publicly
available breast cancer gene expression data sets (microarrays).
Because the estrogen receptor plays a critical role in breast cancer,
we ﬁrst analyzed gene expression proﬁles of RHBDD2 relative to ERα
status. Statistical analysis showed that RHBDD2 expression was not
associated with ERα status of primary breast carcinomas (p=0.148).
This result is in agreement with our previously described data
regarding RHBDD2 gene/protein expression in primary breast carci-
nomas obtained by SAGE and IHC studies.
Next, we analyzed RHBDD2 expression with patient's outcome
using the microarray data set of Van de Vijver et al [10].
Interestingly, we identiﬁed a signiﬁcant association between high
expression of RHBDD2 and short time relapse-free survival among
295 patients (p=0.018; Fig. 7A). Kaplan–Meier analysis revealed
that RHBDD2 over-expression was particularly associated with
shorter overall survival (p=0.0023; Fig. 7B), metastasis-free
interval (p=0.006; Fig. 7C), and relapse-free survival (p=0.013;
Fig. 7D) but surprisingly only in patients with ERα-negative breast
carcinomas. Non-statistically signiﬁcant associations were found for
RHBDD2 expression and follow-up in patients with ERα-positive
carcinomas (pN0.05).
4. Discussion
In a recent study using SAGE, we performed a comparative global
gene expression proﬁle of primary invasive breast carcinomas [1].RHBDD2 and β-actin (ACTB) mRNAs in AccuTarget™ negative control siRNA (siRNA-Ct)
unoﬂuorescence analysis of RHBDD2 protein expression (green ﬂuorescence) in siRNA-
ide (red ﬂuorescence). (C) Analysis of relative proliferation rates in MCF7 breast cancer
e CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega, USA). Each
Fig. 7. RHBDD2 gene expression proﬁle and breast cancer patient follow-up based on a publicly available DNA microarray data set. (A) Relapse-free survival of 295 patients grouped
according to low or high RHBDD2 gene expression levels of the primary invasive breast carcinomas (226 ERα-positive and 69 ERα-negative breast samples). Kaplan–Meier curves of
overall survival (B), metastasis-free interval (C), and relapse-free survival (D) of 69 patients with ERα-negative primary invasive breast carcinomas based on high or low expression
levels of RHBDD2 gene. Kaplan–Meier analysis was assessed using the Van de Vijver et al. data set [10].
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carcinoma which differed in their lymph node status, suggesting
that lymph node status leads to a global distinct expression proﬁle.
In this study, we identiﬁed a rhomboid-like family member gene
known as RHBDD2 to be up-regulated in lymph node (+) breast
carcinomas compared with lymph node (−) counterparts. Real-time
RT-PCR analysis of an independent set of breast carcinomas
demonstrated statistically signiﬁcant RHBDD2 over-expression in
the primary breast cancers from patients that recurred within
6 years of follow-up [1].
In the present study, we ﬁrst determined the human rhomboid-
like family member gene expression proﬁle in a set of 46 normal and
breast carcinoma SAGE libraries. We found that the RHBDD2 transcript
was readily detectable in almost all primary invasive breast carcinoma
and over-expressed compared to normal breast samples. In addition, a
second human rhomboid-like gene, RHBDF1 (Rhomboid family-1
gene), was identiﬁed as highly expressed in primary invasive breast
SAGE libraries. Interestingly, in a recent study Yan et al. showed that
RHBDF1 is signiﬁcantly elevated in invasive ductal carcinomas at both
mRNA and protein levels, and also seems important for breast cancer
cell growth in vivo and in vitro [16].
We further explored RHBDD2 protein expression in 213 breast
tissue samples by immunohistochemistry. This study conﬁrmed theSAGE observations, showing that RHBDD2 protein is highly
expressed in primary invasive breast carcinoma stage III and
lymph node metastasis. However, this study also found that
RHBDD2 was highly expressed in some DCIS, suggesting that
RHBDD2 expression may occur early in the development of cancer.
Interestingly, we detected that normal breast tissue adjacent to
invasive breast carcinomas showed moderate or strong RHBDD2
expression while normal breast epithelium from mammoplastic
specimens showed to be predominantly negative for RHBDD2
expression. This observation of abnormal high RHBDD2 expression
in mammary epithelium adjacent to cancer allows us to speculate
that expression of this protein could be inﬂuenced by the tumor
microenvironment. It is possible that autocrine or paracrine stimuli
maybe operative in modulating RHBDD2 expression in mammary
epithelial cells.
Tumor-speciﬁc up-regulation of some genes can be attributed to
aberrant DNA ampliﬁcation, a phenomenon frequently found in many
breast tumors [12]. Usually genomic ampliﬁcation in cancer involves
genes that provide some sort of growth advantage or transformation
to the cells bearing the ampliﬁcation. Typically ampliﬁcation involves
growth factors, growth factor receptors, certain cyclins, transcription
factors or co-activators, i.e. positive regulators of proliferation and by
deﬁnition many are dubbed oncogenes. Interestingly, microarray-
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reporting ampliﬁcation of the chromosomal region 7q11.2 (the same
region to which RHBDD2maps) in breast cancer cell lines and primary
breast carcinomas [12,15]. Moreover, a genome-wide transcriptome
map revealed clusters of genes located at 7q11.2 exhibiting non-
random increased expression in breast cancer cells [17]. To determine
whether RHBDD2 was also ampliﬁed and over-expressed in breast
tumors, we studied 98 primary invasive breast carcinomas for gene
ampliﬁcation and protein expression by RG-PCR and IHC respectively.
RHBDD2 was ampliﬁed in 21% of the analyzed samples. Although,
almost all ampliﬁed samples showed moderate to strong RHBDD2
protein expression, some breast carcinomas showed over-expression
of RHBDD2 in the absence of gene ampliﬁcation, suggesting in addi-
tion an up-regulation of expression by transcriptional regulatory
means. We also determined that RHBDD2 over-expression in cell lines
MCF7 and T47D was likely the result of ampliﬁcation of chromosome
region 7q11.23. In addition, we identiﬁed and characterized the
expression of two alternative spliced RHBDD2mRNA isoforms in these
breast cancer cell lines.
Interestingly, in a recent study Yan et al. demonstrated that
abrogation of RHBDF1 expression in MDA-MB435 cells and in head
and neck squamous cancer cell line 1483 leads to inhibition of cell
proliferation. siRNA-mediated RHBDF1 silencing results in apoptosis
in breast cancer cells and inhibition of xenograft tumor growth in vivo
[16]. More importantly, in a very recently study Zou et al. demon-
strated that RHBDF1 participates in the modulation of G protein-
coupled receptor-mediated EGFR transactivation. Furthermore,
RHBDF1 over-expression in head and neck cancer cells results in
facilitated export of TGFα [18]. These data suggest that RHBDF1 plays a
critical role in the mechanism responsible for the production of
activated EGFR ligand. Similar to the observations of Yan et al. [16] in
our studies we found that siRNA-mediated silencing of RHBDD2
expression in MCF7 breast cancer cell line leads to a marked decrease
in cell proliferation. Thus, the possibility exists that RHBDD2 may also
play a role in signaling pathways related to cell proliferation/survival
as shown for RHDBF1; as such it could be a protein of relevance in
breast cancer initiation and progression. Interestingly, and supporting
this speculation, in silico analyses revealed that patients whose
tumors expressed high RHBDD2 had signiﬁcantly shorter relapse-
free survival when compared with those whose tumors had low
RHBDD2 levels. More importantly, we found that high RHBDD2
expression was signiﬁcantly associated with shorter overall survival,
relapse-free survival, and metastasis-free interval in patients with
ERα-negative breast carcinomas. These data are in line with our
observation that increased RHBDD2 protein expression is associated
with advanced tumor stages. In addition, we further conﬁrmed our
initial ﬁnding in which we observed a statistically signiﬁcant over-
expression of RHBDD2 in primary tumors of patients who after follow-
up developed recurrent disease [1]. In summary, our ﬁndings indicate
that RHBDD2 over-expressionmight play a role in breast cancer tumor
progression facilitating the development of more aggressive pheno-
types in at least a subset of breast carcinomas. Further studies are
required to elucidate the exact role of this protein in breast cancer.5. Competing interests statement
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